A Phase 2 interventional study of CIN-102 Dose 1 and CIN-102 Dose 2 in Gastroparesis, sponsored by CinDome Pharma, Inc.. Terminated at 19 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-03-25.
Sponsored by CinDome Pharma, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 184 studies in Gastroparesis with a site in United States — 33 open to participants now, 41 under way, 2 of them phase 3. Gastroparesis · United States.
Among the 184 studies in Gastroparesis with a site in United States, this one is the 47th largest by enrollment of the 136 interventional ones that give a count, is one of 17 that started in 2019, is one of 38 in phase 2, and was the 110th registered.
323 studies on the registry are indexed under Gastroparesis; 75 are open to participants now.
Browse Gastroparesis studies →33 of the 184 studies in Gastroparesis with a site in United States are open now. Recruiting first, the newest first:
Evan (Huiliang) Wang · Sites in United States
Ages 18–70
Indiana University · Sites in United States
Ages 18+
Ohio State University · Sites in United States
Ages 18+
Ohio State University · Sites in United States
Ages 18–65
Viral N. Shah · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 49 Gastroparesis studies recruiting now, 25 (51%) set no upper age limit and 14 (29%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
184 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 42 · Phase 3 14 · Phase 4 6
First in 2002; this study’s year is marked. 17 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is above the median of 42 across 215 interventional studies indexed under Gastroparesis.
Median enrollment 36 across the 136 interventional studies, 108 across the 39 observational. Of the 124 that completed or were terminated, 63 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
55 of 184 have an industry lead sponsor. The 10 most frequent:
CinDome Pharma, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.
CinDome Pharma, Inc. has 4 studies filed under Gastroparesis — fewer than ten, so there is no comparison to draw.
14 of the studies in Gastroparesis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01696734Phase 3M.D. Anderson Cancer CenterDomperidone in Treating Patients With Gastrointestinal Disorders | 2027-10-31 |
| NCT04506593Indiana UniversityIndiana University Gastrointestinal Motility Diagnosis Registry | 2026-11 |
| NCT06046833Samita GargContinuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes | 2026-12 |
| NCT02165059Indiana UniversityGI Neuromuscular Pathology Prospective Registry | 2026-12 |
| NCT04282317Indiana UniversityMagnetic Resonance Imaging of the Brain and Stomach in Healthy Volunteers and Gastroparesis | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 184 studies in Gastroparesis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, placebo-controlled Phase 2A study to evaluate safety, efficacy, PK, and dose response of oral CIN-102 in adults with idiopathic and diabetic gastroparesis. The study will assess three oral doses of CIN-102 versus placebo in three separate cohorts.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CIN-102 tablets by mouth twice daily for 14 days
Drug: CIN-102 Dose 1
Placebo tablets by mouth twice daily for 14 days
Drug: Placebo
CIN-102 tablets by mouth twice daily for 14 days
Drug: CIN-102 Dose 2
Placebo tablets by mouth twice daily for 14 days
Drug: Placebo
CIN-102 tablets by mouth twice daily for 14 days
Drug: CIN-102 Dose 3
Placebo tablets by mouth twice daily for 14 days
Drug: Placebo
Drug pages: CIN-102 · Deudomperidone
CIN-102 Dose 1
Drug pages: CIN-102 · Deudomperidone
CIN-102 Dose 2
Drug pages: CIN-102 · Deudomperidone
CIN-102 Dose 3
Placebo
The Change From Baseline in Gastric Emptying (GE) as Measured by the Gastric Emptying Breath Test (GEBT) Half-Time (T1/2)
The GEBT is a nonradioactive, noninvasive, orally administered test for measuring the rate of solid phase gastric emptying (GE), after consumption of a standardized 13C-enriched meal. GEBT T1/2 is the time for half of the ingested meal to leave the stomach. It is reported using kPCD, a mathematical expression of a test subject's 13CO2 excretion rate per minute at any measurement time t relative to the dose of 13C contained in the test meal.
Time frame: Baseline (gathered between Days -10 to -3, prior to first dose of study drug) to Day 14
The Percent Change From Baseline in Gastric Emptying (GE) as Measured by the Gastric Emptying Breath Test (GEBT) Half-Time (T1/2)
The GEBT is a nonradioactive, noninvasive, orally administered test for measuring the rate of solid phase gastric emptying (GE), after consumption of a standardized 13C-enriched meal. GEBT T1/2 is the time for half of the ingested meal to leave the stomach. It is reported using kPCD, a mathematical expression of a test subject's 13CO2 excretion rate per minute at any measurement time t relative to the dose of 13C contained in the test meal.
Time frame: Baseline (gathered between Days -10 to -3, prior to first dose of study drug) to Day 14
The Change From Baseline in GE as Measured by the GEBT Excretion Rate
The value and change from baseline in GEBT excretion rate (kPCD per minute) were summarized by treatment group. The value and time-matched (to baseline visit) change from baseline of the GEBT results for each post-meal time point were also summarized by treatment group.
Time frame: Baseline (gathered between Days -10 to -3, prior to first dose of study drug) to Day 14
The Percent Change From Baseline in GE as Measured by the GEBT Excretion Rate
The percent change from baseline in GEBT excretion rate (kPCD per minute) was summarized by treatment group. The percent change from baseline of the GEBT results for each post-meal time point was also summarized by treatment group.
Time frame: Baseline (gathered between Days -10 to -3, prior to first dose of study drug) to Day 14
The Change From Baseline in ANMS GCSI-DD Total Scores
American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD) total and subscale scores and change from baseline for the Intent to Treat Population using the protocol-specified scoring method and the manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
Time frame: Baseline (mean score for the 3 days preceding randomization) to Day 14
The Percent Change From Baseline in ANMS GCSI-DD Total Scores
American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary(ANMS GCSI-DD) total and subscale scores percent change from baseline for the Intent to Treat Population using the protocol-specified scoring method and the manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
Time frame: Baseline (mean score for the 3 days preceding randomization) to Day 14
The Change From Baseline in ANMS GCSI-DD Subscale Scores - Upper Abdominal Pain
American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD) subscale scores and change from baseline for the Intent to Treat Population using the manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
Time frame: Baseline (mean score for the 3 days preceding randomization) to Day 14
The Percent Change From Baseline in ANMS GCSI-DD Subscale Scores - Upper Abdominal Pain
American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary(ANMS GCSI-DD) subscale scores percent change from baseline for the Intent to Treat Population using the protocol-specified scoring method and the manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
Time frame: Baseline (mean score for the 3 days preceding randomization) to Day 14
The Change From Baseline in ANMS GCSI-DD Subscale Scores - Bloating Subscale Score
American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD) subscale scores and change from baseline for the Intent to Treat Population using the protocol-specified scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
Time frame: Baseline (mean score for the 3 days preceding randomization) to Day 14
The Percent Change From Baseline in ANMS GCSI-DD Subscale Scores - Bloating Subscale Score
American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary(ANMS GCSI-DD) subscale scores percent change from baseline for the Intent to Treat Population using the protocol-specified scoring method and the manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
Time frame: Baseline (mean score for the 3 days preceding randomization) to Day 14
The Change From Baseline in ANMS GCSI-DD Subscale Scores - Nausea/Vomiting
American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD) subscale scores and change from baseline for the Intent to Treat Population using the protocol-specified scoring method and manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
Time frame: Baseline (mean score for the 3 days preceding randomization) to Day 14
The Percent Change From Baseline in ANMS GCSI-DD Subscale Scores - Nausea/Vomiting
American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary(ANMS GCSI-DD) subscale scores percent change from baseline for the Intent to Treat Population using the protocol-specified scoring method and the manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
Time frame: Baseline (mean score for the 3 days preceding randomization) to Day 14
The Change From Baseline in ANMS GCSI-DD Subscale Scores - Postprandial Fullness/Early Satiety
American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD) subscale scores and change from baseline for the Intent to Treat Population using the protocol-specified scoring method and manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
Time frame: Baseline (mean score for the 3 days preceding randomization) to Day 14 (+/- 2 days)
The Percent Change From Baseline in ANMS GCSI-DD Subscale Scores - Postprandial Fullness/Early Satiety
American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary(ANMS GCSI-DD) subscale scores percent change from baseline for the Intent to Treat Population using the protocol-specified scoring method and the manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
Time frame: Baseline (mean score for the 3 days preceding randomization) to Day 14 (+/- 2 days)
Pharmacokinetics (PK) Characterization of Multiple Doses of CIN-102: Maximum Observed Concentration (CMAX) - Day 1
CMAX is defined as the maximum observed drug concentration after administration.
Time frame: Day 1 (single dose)
Pharmacokinetics (PK) Characterization of Multiple Doses of CIN-102: Maximum Observed Concentration (CMAX) - Day 14
CMAX is defined as the maximum observed drug concentration after administration.
Time frame: Day 14 (steady state)
Pharmacokinetics (PK) Characterization of Multiple Doses of CIN-102: Time of Occurrence of CMAX (TMAX) - Day 14
TMAX is defined as the time to maximum plasma concentration.
Time frame: Day 14 (steady state)
Pharmacokinetics (PK) Characterization of Multiple Doses of CIN-102: Time of Occurrence of CMAX (TMAX) - Day 1
TMAX is defined as the time to maximum plasma concentration.
Time frame: Day 1 (single dose)
Pharmacokinetics (PK) Characterization of Multiple Doses of CIN-102: Area Under the Plasma Concentration-time Curve From Pre-dose (Time 0) to 12 Hours (AUC0-12)
AUC0-12 is defined as the area under the plasma concentration-time curve from pre-dose (Time 0) to 12 Hours on Day 1 of CIN-102 dosing.
Time frame: Day 1 (single dose), Time 0 to 12 hours
Pharmacokinetics (PK) Characterization of Multiple Doses of CIN-102: Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUCtau)
AUCtau is defined as the area under the plasma concentration-time curve over the dosing interval.
Time frame: Day 14 (steady state)
The Change From Baseline in PAGI-SYM Total Score
Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) total score and change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
Time frame: Baseline (last available assessment prior to the first dose of study drug) to Day 14
The Percent Change From Baseline in PAGI-SYM Total Score
Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) total score percent change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
Time frame: Baseline (last available assessment prior to the first dose of study drug) to Day 14
The Change From Baseline in PAGI-SYM Subscale Score - Heartburn/Regurgitation
Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score and change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
Time frame: Baseline (last available assessment prior to the first dose of study drug) to Day 14
The Percent Change From Baseline in PAGI-SYM Subscale Score - Heartburn/Regurgitation
Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score percent change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
Time frame: Baseline (last available assessment prior to the first dose of study drug) to Day 14
The Change From Baseline in PAGI-SYM Subscale Score - Fullness/Early Satiety
Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score and change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
Time frame: Baseline (last available assessment prior to the first dose of study drug) to Day 14
The Percent Change From Baseline in PAGI-SYM Subscale Score - Fullness/Early Satiety
Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score percent change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
Time frame: Baseline (last available assessment prior to the first dose of study drug) to Day 14
The Change From Baseline in PAGI-SYM Subscale Score - Nausea/Vomiting
Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score and change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
Time frame: Baseline (last available assessment prior to the first dose of study drug) to Day 14
The Percent Change From Baseline in PAGI-SYM Subscale Score - Nausea/Vomiting
Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score percent change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
Time frame: Baseline (last available assessment prior to the first dose of study drug) to Day 14
The Change From Baseline in PAGI-SYM Subscale Score - Bloating
Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score and change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
Time frame: Baseline (last available assessment prior to the first dose of study drug) to Day 14
The Percent Change From Baseline in PAGI-SYM Subscale Score - Bloating
Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score percent change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
Time frame: Baseline (last available assessment prior to the first dose of study drug) to Day 14
The Change From Baseline in PAGI-SYM Subscale Scores - Upper Abdominal Pain
Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score and change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
Time frame: Baseline (last available assessment prior to the first dose of study drug) to Day 14
The Percent Change From Baseline in PAGI-SYM Subscale Scores - Upper Abdominal Pain
Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score percent change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
Time frame: Baseline (last available assessment prior to the first dose of study drug) to Day 14
The Change From Baseline in PAGI-SYM Subscale Score - Lower Abdominal Pain
Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score and change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
Time frame: Baseline (last available assessment prior to the first dose of study drug) to Day 14
The Percent Change From Baseline in PAGI-SYM Subscale Score - Lower Abdominal Pain
Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score percent change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
Time frame: Baseline (last available assessment prior to the first dose of study drug) to Day 14
Clinical Grading Assessment Scale at Day 14
The Clinical Grading Assessment Scale is a patient and investigator reported outcome instrument for a clinical trial endpoint. Completed at Day 14, the assessment asks subjects about how their stomach/gastroparesis-related problems/symptoms compare to the period before they started treatment in the study based on a 15-point likert scale, where +7 is completely better, 0 is no change, and -7 is very much worse.
Time frame: Day 14
This study was initiated on 11 September 2019 and completed on 17 December 2020 across 15 clinical sites in the United States (US). A total of 60 participants with idiopathic or diabetic gastroparesis were planned to be enrolled.
| Milestone | Cohort 1 - 10 mg BID | Cohort 2 - 20 mg QD | Cohort 3 - 5 mg BID | Placebo (Pooled) |
|---|---|---|---|---|
| Started | 30 | 15 | 9 | 18 |
| Completed | 29 | 15 | 9 | 18 |
| Not completed | 1 | 0 | 0 | 0 |
| Withdrew: Randomized in error by the site | 1 | 0 | 0 | 0 |
The GEBT is a nonradioactive, noninvasive, orally administered test for measuring the rate of solid phase gastric emptying (GE), after consumption of a standardized 13C-enriched meal. GEBT T1/2 is the time for half of the ingested meal to leave the stomach. It is reported using kPCD, a mathematical expression of a test subject's 13CO2 excretion rate per minute at any measurement time t relative to the dose of 13C contained in the test meal.
| Minutes | Cohort 1 - 10 mg BID | Cohort 1 - Placebo | Cohort 2 - 20 mg QD | Cohort 2- Placebo | Cohort 3- 5 mg BID | Cohort 3- Placebo |
|---|---|---|---|---|---|---|
| T 1/2 Baseline | 132.97 ± 36.228 | 119 ± 34.654 | 123.25 ± 34.394 | 138.07 ± 54.684 | 162.90 ± 12.587 | — |
| T 1/2 Day 14 | 123.16 ± 30.881 | 111.45 ± 20.923 | 125.70 ± 44.190 | 197.80 | — | — |
| T 1/2 Change from baseline to Day 14 | -10.60 ± 37.240 | -8.05 ± 35.640 | -12.37 ± 17.621 | 6.20 | — | — |
The GEBT is a nonradioactive, noninvasive, orally administered test for measuring the rate of solid phase gastric emptying (GE), after consumption of a standardized 13C-enriched meal. GEBT T1/2 is the time for half of the ingested meal to leave the stomach. It is reported using kPCD, a mathematical expression of a test subject's 13CO2 excretion rate per minute at any measurement time t relative to the dose of 13C contained in the test meal.
| Percent change in GE time | Cohort 1 - 10 mg BID | Cohort 1 - Placebo | Cohort 2 - 20 mg QD | Cohort 2- Placebo | Cohort 3- 5 mg BID | Cohort 3- Placebo |
|---|---|---|---|---|---|---|
| The Percent Change From Baseline in Gastric Emptying (GE) as Measured by the Gastric Emptying Breath Test (GEBT) Half-Time (T1/2) | -4.23 ± 24.278 | -1.35 ± 26.533 | -9.27 ± 11.304 | 3.24 | — | — |
The value and change from baseline in GEBT excretion rate (kPCD per minute) were summarized by treatment group. The value and time-matched (to baseline visit) change from baseline of the GEBT results for each post-meal time point were also summarized by treatment group.
| kPCD min-1 | Cohort 1- 10 mg BID | Cohort 1 - Placebo | Cohort 2- 20 mg QD | Cohort 2- Placebo | Cohort 3- 5 mg BID | Cohort 3- Placebo |
|---|---|---|---|---|---|---|
| GEBT 45 minutes post meal consumption - Baseline | 8.88 ± 4.113 | 9.56 ± 6.040 | 11.39 ± 3.680 | 8.37 ± 5.132 | 7.50 ± 4.950 | — |
| GEBT 45 minutes post meal consumption - Day 14 | 10.74 ± 3.038 | 10.70 ± 3.266 | 10.39 ± 4.534 | 4.10 | — | — |
| GEBT 45 minutes post meal consumption - Change from Baseline to Day 14 | 1.96 ± 4.091 | 1.14 ± 6.210 | -1.07 ± 3.475 | 1.40 | — | — |
| GEBT 90 minutes post meal consumption - Baseline | 20.53 ± 9.016 | 23.55 ± 10.522 | 23.30 ± 9.349 | 23.10 ± 12.443 | 16.75 ± 10.960 | — |
| GEBT 90 minutes post meal consumption - Day 14 | 23.60 ± 6.128 | 25.10 ± 6.551 | 22.01 ± 10.889 | 4.20 | — | — |
| GEBT 90 minutes post meal consumption - Change from baseline to Day 14 | 3.37 ± 9.287 | 1.55 ± 10.056 | 1.96 ± 5.962 | -8.80 | — | — |
| GEBT 120 minutes post meal consumption - Baseline | 29.02 ± 11.549 | 31.45 ± 12.536 | 31.04 ± 12.264 | 21.453 ± 25.60 | 21.50 ± 7.212 | — |
| GEBT 120 minutes post meal consumption - Day 14 | 32.68 ± 8.901 | 33.61 ± 9.146 | 32.40 ± 14.678 | 7.20 | — | — |
| GEBT 120 minutes post meal consumption - Change from baseline to Day 14 | 3.86 ± 11.008 | 2.16 ± 11.547 | 6.03 ± 7.958 | -6.30 | — | — |
| GEBT 150 minutes post meal consumption - Baseline | 35.97 ± 12.946 | 36.89 ± 11.820 | 37.94 ± 13.855 | 36.33 ± 23.427 | 25.90 ± 0.849 | — |
| GEBT 150 minutes post meal consumption - Day 14 | 37.13 ± 10.002 | 39.23 ± 8.021 | 35.30 ± 16.488 | 8.90 | — | — |
| GEBT 150 minutes post meal consumption - Change from baseline to Day 14 | 1.25 ± 12.261 | 2.34 ± 10.324 | 2.46 ± 7.241 | -6.80 | — | — |
| GEBT 180 minutes post meal consumption - Baseline | 39.02 ± 13.258 | 40.94 ± 12.526 | 40.66 ± 12.536 | 38.70 ± 20.044 | 30.70 ± 7.778 | — |
| GEBT 180 minutes post meal consumption - Day 14 | 40.96 ± 11.080 | 43.67 ± 8.078 | 36.91 ± 14.398 | 15.20 | — | — |
| GEBT 180 minutes post meal consumption - Change from baseline to Day 14 | 1.85 ± 12.445 | 2.74 ± 10.959 | 0.37 ± 5.949 | -5.50 | — | — |
| GEBT 240 minutes post meal consumption - Baseline | 41.89 ± 12.750 | 41.85 ± 8.953 | 42.07 ± 11.951 | 40.50 ± 9.000 | 29.85 ± 13.223 | — |
| GEBT 240 minutes post meal consumption - Day 14 | 41.41 ± 10.422 | 44.57 ± 7.928 | 37.28 ± 10.679 | 20.40 | — | — |
| GEBT 240 minutes post meal consumption - Change from baseline to Day 14 | -0.79 ± 11.821 | 2.73 ± 8.144 | -3.34 ± 5.496 | -11.10 | — | — |
The percent change from baseline in GEBT excretion rate (kPCD per minute) was summarized by treatment group. The percent change from baseline of the GEBT results for each post-meal time point was also summarized by treatment group.
| Percent change in GEBT excretion rate | Cohort 1- 10 mg BID | Cohort 1 - Placebo | Cohort 2- 20 mg QD | Cohort 2- Placebo | Cohort 3- 5 mg BID | Cohort 3- Placebo |
|---|---|---|---|---|---|---|
| GEBT 45 minutes post meal consumption - Percent change from Baseline to Day 14 | 89.31 ± 266.803 | -679.95 ± 2500.333 | -7.99 ± 28.243 | 51.85 | — | — |
| GEBT 90 minutes post meal consumption - Percent change from baseline to Day 14 | 56.73 ± 125.218 | 43.43 ± 117.796 | 15.73 ± 41.144 | -67.69 | — | — |
| GEBT 120 minutes post meal consumption - Percent change from baseline to Day 14 | 40.17 ± 102.994 | 29.78 ± 83.476 | 25.37 ± 34.722 | -46.67 | — | — |
| GEBT 150 minutes post meal consumption - Percent change from baseline to Day 14 | 23.46 ± 82.609 | 21.57 ± 64.614 | 7.78 ± 23.087 | -43.31 | — | — |
| GEBT 180 minutes post meal consumption - Percent change from baseline to Day 14 | 20.31 ± 65.491 | 17.80 ± 46.488 | 1.40 ± 15.573 | -26.57 | — | — |
| GEBT 240 minutes post meal consumption - Percent change from baseline to Day 14 | 9.46 ± 58.567 | 9.87 ± 25.864 | -5.31 ± 18.076 | -35.24 | — | — |
American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD) total and subscale scores and change from baseline for the Intent to Treat Population using the protocol-specified scoring method and the manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
| score on a scale | Cohort 1 - 10 mg BID | Cohort 1 - Placebo | Cohort 2 - 20 mg QD | Cohort 2- Placebo | Cohort 3- 5 mg BID | Cohort 3- Placebo |
|---|---|---|---|---|---|---|
| Protocol Scoring Method - Baseline | 2.42 ± 0.666 | 2.40 ± 0.464 | 2.40 ± 0.530 | 2.33 ± 0.276 | 2.33 ± 0.583 | 2.81 ± 0.594 |
| Protocol Scoring Method - Day 14 | 1.40 ± 0.731 | 1.23 ± 0.870 | 1.08 ± 0.866 | 0.83 ± 0.694 | 1.78 ± 1.051 | 1.33 ± 0.882 |
| Protocol Scoring Method - Change from baseline to Day 14 | -1.04 ± 0.612 | -1.18 ± 0.754 | -1.33 ± 0.864 | -1.50 ± 0.803 | -0.56 ± 0.665 | -1.48 ± 1.233 |
| Manual Scoring Method - Baseline | 2.14 ± 0.954 | 2.15 ± 0.414 | 2.13 ± 0.495 | 2.18 ± 0.450 | 2.16 ± 0.567 | 2.56 ± 0.454 |
| Manual Scoring Method - Day 14 | 1.17 ± 0.582 | 1.04 ± 0.833 | 0.88 ± 0.671 | 0.80 ± 0.730 | 1.47 ± 1.082 | 1.20 ± 0.693 |
| Manual Scoring Method - Change from baseline to Day 14 | -0.98 ± 0.684 | -1.11 ± 0.699 | -1.25 ± 0.831 | -1.38 ± 0.672 | -0.69 ± 0.736 | -1.36 ± 0.707 |
American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary(ANMS GCSI-DD) total and subscale scores percent change from baseline for the Intent to Treat Population using the protocol-specified scoring method and the manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
| Percent change in score | Cohort 1- 10 mg BID | Cohort 1 - Placebo | Cohort 2- 20 mg QD | Cohort 2- Placebo | Cohort 3- 5 mg BID | Cohort 3- Placebo |
|---|---|---|---|---|---|---|
| Protocol Scoring Method - Percent change from baseline to Day 14 | -43.64 ± 24.813 | -49.45 ± 33.736 | -55.24 ± 35.011 | -63.25 ± 34.016 | -26.84 ± 31.291 | -48.79 ± 40.507 |
| Manual Scoring Method - Percent change from baseline to Day 14 | -44.07 ± 26.803 | -52.61 ± 33.887 | -55.99 ± 35.840 | -65.05 ± 34.164 | -35.01 ± 36.277 | -52.81 ± 28.361 |
American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD) subscale scores and change from baseline for the Intent to Treat Population using the manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
| score on a scale | Cohort 1 - 10 mg BID | Cohort 1 - Placebo | Cohort 2 - 20 mg QD | Cohort 2- Placebo | Cohort 3 - 5 mg BID | Cohort 3- Placebo |
|---|---|---|---|---|---|---|
| Manual Scoring Method - Baseline | 1.79 ± 1.160 | 1.94 ± 0.841 | 1.96 ± 0.872 | 2.08 ± 0.833 | 2.19 ± 1.042 | 2.11 ± 1.171 |
| Manual Scoring Method - Day 14 | 0.97 ± 0.906 | 0.73 ± 0.786 | 0.87 ± 0.743 | 1.00 ± 1.155 | 1.33 ± 1.414 | 1.33 ± 1.155 |
| Manual Scoring Method - Change from baseline to Day 14 | -0.80 ± 1.093 | -1.21 ± 0.981 | -1.09 ± 1.065 | -1.08 ± 0.957 | -0.85 ± 0.988 | -0.78 ± 0.694 |
American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary(ANMS GCSI-DD) subscale scores percent change from baseline for the Intent to Treat Population using the protocol-specified scoring method and the manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
| Percent change in score | Cohort 1 - 10 mg BID | Cohort 1 - Placebo | Cohort 2 - 20 mg QD | Cohort 2- Placebo | Cohort 3- 5 mg BID | Cohort 3- Placebo |
|---|---|---|---|---|---|---|
| The Percent Change From Baseline in ANMS GCSI-DD Subscale Scores - Upper Abdominal Pain | -50.43 ± 47.000 | -59.74 ± 44.230 | -41.03 ± 79.068 | -58.33 ± 50.000 | -43.15 ± 45.854 | -46.67 ± 50.332 |
American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD) subscale scores and change from baseline for the Intent to Treat Population using the protocol-specified scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
| score on a scale | Cohort 1 - 10 mg BID | Cohort 1 - Placebo | Cohort 2 - 20 mg QD | Cohort 2- Placebo | Cohort 3 - 5 mg BID | Cohort 3- Placebo |
|---|---|---|---|---|---|---|
| Protocol Specified Scoring Method - Baseline | 2.80 ± 0.824 | 2.82 ± 0.480 | 2.87 ± 0.710 | 2.58 ± 0.500 | 2.70 ± 0.696 | 3.11 ± 1.018 |
| Protocol Specified Scoring Method - Day 14 | 1.76 ± 1.123 | 1.45 ± 0.934 | 1.47 ± 1.356 | 1.00 ± 0.816 | 2.33 ± 1.118 | 1.67 ± 1.518 |
| Protocol Specified Scoring Method - Change from baseline to Day 14 | -1.08 ± 0.785 | -1.36 ± 0.994 | -1.40 ± 1.121 | -1.58 ± 1.258 | -0.37 ± 0.655 | -1.44 ± 2.219 |
American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary(ANMS GCSI-DD) subscale scores percent change from baseline for the Intent to Treat Population using the protocol-specified scoring method and the manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
| Percent change in score | Cohort 1 - 10 mg BID | Cohort 1 - Placebo | Cohort 2 - 20 mg QD | Cohort 2- Placebo | Cohort 3 - 5 mg BID | Cohort 3- Placebo |
|---|---|---|---|---|---|---|
| The Percent Change From Baseline in ANMS GCSI-DD Subscale Scores - Bloating Subscale Score | -41.78 ± 32.337 | -46.73 ± 35.270 | -51.82 ± 41.422 | -55.95 ± 41.582 | -16.16 ± 26.339 | -33.33 ± 76.376 |
American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD) subscale scores and change from baseline for the Intent to Treat Population using the protocol-specified scoring method and manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
| score on a scale | Cohort 1 - 10 mg BID | Cohort 1 - Placebo | Cohort 2 - 20 mg QD | Cohort 2- Placebo | Cohort 3 | Cohort 3- Placebo |
|---|---|---|---|---|---|---|
| Protocol Scoring Method - Baseline | 1.62 ± 0.752 | 1.55 ± 0.757 | 1.60 ± 0.623 | 1.79 ± 0.798 | 1.52 ± 0.556 | 2.00 ± 0.500 |
| Protocol Scoring Method - Day 14 | 0.74 ± 0.561 | 0.59 ± 1.020 | 0.40 ± 0.431 | 0.38 ± 0.479 | 1.00 ± 1.061 | 0.50 ± 0.500 |
| Protocol Scoring Method - Change from baseline to Day 14 | -0.89 ± 0.820 | -0.95 ± 0.583 | -1.20 ± 0.812 | -1.42 ± 0.776 | -0.52 ± 0.719 | -1.50 ± 0.866 |
| Manual Scoring Method - Nausea Baseline | 2.52 ± 0.786 | 2.45 ± 0.563 | 2.67 ± 0.854 | 2.33 ± 0.903 | 2.59 ± 0.778 | 3.00 ± 0.000 |
| Manual Scoring Method - Nausea Day 14 | 1.34 ± 1.010 | 0.82 ± 0.982 | 0.73 ± 0.799 | 0.75 ± 0.957 | 1.67 ± 1.323 | 1.00 ± 1.000 |
| Manual Scoring Method - Nausea Change from baseline to Day 14 | -1.20 ± 0.994 | -1.64 ± 0.912 | -1.93 ± 1.476 | -1.58 ± 0.788 | -0.93 ± 0.997 | -2.00 ± 1.000 |
| Manual Scoring Method - Vomiting Baseline | 0.71 ± 1.020 | 0.64 ± 1.206 | 0.53 ± 0.764 | 1.25 ± 0.918 | 0.44 ± 0.577 | 1.00 ± 1.000 |
| Manual Scoring Method - Vomiting Day 14 | 0.14 ± 0.351 | 0.36 ± 1.206 | 0.07 ± 0.258 | 0.00 ± 0.000 | 0.33 ± 1.000 | 0.00 ± 0.000 |
| Manual Scoring Method - Vomiting Change from baseline to Day 14 | -0.59 ± 0.937 | -0.27 ± 0.467 | -0.47 ± 0.627 | -1.25 ± 0.918 | -0.11 ± 0.645 | -1.00 ± 1.000 |
American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary(ANMS GCSI-DD) subscale scores percent change from baseline for the Intent to Treat Population using the protocol-specified scoring method and the manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
| Percent change in score | Cohort 1 - 10 mg BID | Cohort 1 - Placebo | Cohort 2 - 20 mg QD | Cohort 2- Placebo | Cohort 3 | Cohort 3- Placebo |
|---|---|---|---|---|---|---|
| Protocol Scoring Method - Percent change from baseline to Day 14 | -52.41 ± 37.374 | -69.49 ± 38.394 | -67.94 ± 34.799 | -81.36 ± 25.729 | -41.08 ± 47.221 | -72.22 ± 25.459 |
| Manual Scoring Method - Nausea Percent change from baseline to Day 14 | -48.88 ± 37.271 | -68.35 ± 38.399 | 38.399 ± 42.230 | -73.96 ± 32.342 | -41.32 ± 43.189 | -66.67 ± 33.333 |
| Manual Scoring Method - Vomiting Percent Change from baseline to Day 14 | -71.73 ± 75.756 | -80.00 ± 44.721 | -94.64 ± 15.152 | -100.00 ± 0.000 | -64.00 ± 80.498 | -100.00 ± 0.000 |
American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD) subscale scores and change from baseline for the Intent to Treat Population using the protocol-specified scoring method and manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
| score on a scale | Cohort 1 - 10 mg BID | Cohort 1 - Placebo | Cohort 2 - 20 mg QD | Cohort 2- Placebo | Cohort 3 | Cohort 3- Placebo |
|---|---|---|---|---|---|---|
| Protocol Specified Scoring Method - Baseline | 2.84 ± 0.674 | 2.85 ± 0.575 | 2.74 ± 0.630 | 2.63 ± 0.250 | 2.78 ± 0.791 | 3.33 ± 0.577 |
| Protocol Specified Scoring Method - Day 14 | 1.71 ± 0.978 | 1.64 ± 1.027 | 1.37 ± 1.008 | 1.13 ± 0.854 | 2.00 ± 1.146 | 1.83 ± 0.764 |
| Protocol Specified Scoring Method - Change from baseline to Day 14 | -1.16 ± 0.771 | -1.21 ± 0.961 | -1.38 ± 1.011 | -1.50 ± 1.080 | -0.78 ± 0.816 | -1.50 ± 0.866 |
| Manual Scoring Method - Postprandial fullness Baseline | 3.01 ± 0.634 | 3.00 ± 0.471 | 2.84 ± 0.795 | 2.75 ± 0.167 | 2.93 ± 0.760 | 3.44 ± 0.509 |
| Manual Scoring Method - Postprandial fullness Day 14 | 1.79 ± 1.082 | 1.73 ± 1.191 | 1.53 ± 1.125 | 1.25 ± 0.957 | 2.22 ± 1.302 | 2.00 ± 1.000 |
| Manual Scoring Method - Postprandial fullness Change from baseline to Day 14 | -1.24 ± 0.917 | -1.27 ± 1.114 | -1.31 ± 1.116 | -1.50 ± 1.106 | -0.70 ± 1.033 | -1.44 ± 1.262 |
| Manual Scoring Method - Early satiety Baseline | 2.67 ± 0.783 | 2.70 ± 0.722 | 2.64 ± 0.556 | 2.50 ± 0.430 | 2.63 ± 0.873 | 3.22 ± 0.694 |
| Manual Scoring Method - Early satiety Day 14 | 1.62 ± 1.015 | 1.55 ± 0.934 | 1.20 ± 0.941 | 1.00 ± 0.816 | 1.78 ± 1.093 | 1.67 ± 0.577 |
| Manual Scoring Method - Early satiety Change from baseline to Day 14 | -1.08 ± 0.834 | -1.15 ± 0.911 | -1.44 ± 0.948 | -1.50 ± 1.139 | -0.85 ± 0.852 | -1.56 ± 0.509 |
American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary(ANMS GCSI-DD) subscale scores percent change from baseline for the Intent to Treat Population using the protocol-specified scoring method and the manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
| Percent change in score | Cohort 1 - 10 mg BID | Cohort 1 - Placebo | Cohort 2 - 20 mg QD | Cohort 2- Placebo | Cohort 3 | Cohort 3- Placebo |
|---|---|---|---|---|---|---|
| Protocol Specified Scoring Method - Percent change from baseline to Day 14 | -41.38 ± 29.096 | -42.32 ± 36.042 | -50.14 ± 36.594 | -54.75 ± 36.522 | -29.47 ± 32.944 | -44.44 ± 25.459 |
| Manual Scoring Method - Postprandial fullness Percent change from baseline to Day 14 | -41.52 ± 33.646 | -42.90 ± 37.929 | -45.50 ± 38.815 | -53.13 ± 35.904 | -26.11 ± 38.424 | -40.00 ± 36.056 |
| Manual Scoring Method - Early satiety Percent change from baseline to Day 14 | -40.56 ± 31.248 | -40.56 ± 41.704 | -54.88 ± 35.651 | 55.95 ± 41.582 | -30.65 ± 38.876 | -48.61 ± 14.633 |
CMAX is defined as the maximum observed drug concentration after administration.
| ng/mL | Cohort 1 - 10 mg BID | Cohort 2 - 20 mg QD | Cohort 3 - 5 mg BID |
|---|---|---|---|
| Pharmacokinetics (PK) Characterization of Multiple Doses of CIN-102: Maximum Observed Concentration (CMAX) - Day 1 | 10.066 ± 5.6474 | 25.460 ± 16.8212 | 6.730 ± 4.4942 |
CMAX is defined as the maximum observed drug concentration after administration.
| ng/mL | Cohort 1 - 10 mg BID | Cohort 2 - 20 mg QD | Cohort 3 - 5 mg BID |
|---|---|---|---|
| Pharmacokinetics (PK) Characterization of Multiple Doses of CIN-102: Maximum Observed Concentration (CMAX) - Day 14 | 18.176 ± 12.0178 | 36.407 ± 18.9431 | 12.276 ± 10.9355 |
TMAX is defined as the time to maximum plasma concentration.
| h | Cohort 1 - 10 mg BID | Cohort 2 - 20 mg QD | Cohort 3 - 5 mg BID |
|---|---|---|---|
| Pharmacokinetics (PK) Characterization of Multiple Doses of CIN-102: Time of Occurrence of CMAX (TMAX) - Day 14 | 2.000 (0.97 to 4.52) | 2.000 (1.00 to 6.00) | 2.000 (1.00 to 8.00) |
TMAX is defined as the time to maximum plasma concentration.
| h | Cohort 1 - 10 mg BID | Cohort 2 - 20 mg QD | Cohort 3 - 5 mg BID |
|---|---|---|---|
| Pharmacokinetics (PK) Characterization of Multiple Doses of CIN-102: Time of Occurrence of CMAX (TMAX) - Day 1 | 2.000 (0.98 to 6.00) | 2.500 (1.00 to 6.00) | 2.000 (0.98 to 4.05) |
AUC0-12 is defined as the area under the plasma concentration-time curve from pre-dose (Time 0) to 12 Hours on Day 1 of CIN-102 dosing.
| h*ng/mL | Cohort 1 - 10 mg BID | Cohort 2 - 20 mg QD | Cohort 3 - 5 mg BID |
|---|---|---|---|
| Pharmacokinetics (PK) Characterization of Multiple Doses of CIN-102: Area Under the Plasma Concentration-time Curve From Pre-dose (Time 0) to 12 Hours (AUC0-12) | 46.98 ± 22.861 | 104.33 ± 52.267 | 34.73 ± 20.907 |
AUCtau is defined as the area under the plasma concentration-time curve over the dosing interval.
| h*ng/mL | Cohort 1 - 10 mg BID | Cohort 2 - 20 mg QD | Cohort 3 - 5 mg BID |
|---|---|---|---|
| Pharmacokinetics (PK) Characterization of Multiple Doses of CIN-102: Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUCtau) | 100.18 ± 59.796 | 301.94 ± 149.499 | 65.73 ± 34.822 |
Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) total score and change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
| score on a scale | Cohort 1 - 10 mg BID | Cohort 1 - Placebo | Cohort 2 - 20 mg QD | Cohort 2- Placebo | Cohort 3 - 5 mg BID | Cohort 3- Placebo |
|---|---|---|---|---|---|---|
| Baseline | 2.94 ± 0.623 | 3.25 ± 0.495 | 2.72 ± 0.838 | 3.50 ± 0.241 | 3.37 ± 0.658 | 2.86 ± 0.198 |
| Day 14 | 1.97 ± 0.855 | 1.75 ± 0.949 | 1.80 ± 1.251 | 1.60 ± 1.329 | 2.02 ± 1.300 | 1.59 ± 0.638 |
| Change from baseline to Day 14 | -0.97 ± 0.990 | -1.50 ± 1.312 | -0.93 ± 0.806 | -1.90 ± 1.286 | -1.35 ± 1.179 | -1.27 ± 0.660 |
Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) total score percent change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
| Percent change in score | Cohort 1 - 10 mg BID | Cohort 1 - Placebo | Cohort 2 - 20 mg QD | Cohort 2- Placebo | Cohort 3 - 5 mg BID | Cohort 3- Placebo |
|---|---|---|---|---|---|---|
| The Percent Change From Baseline in PAGI-SYM Total Score | -31.18 ± 33.026 | -42.32 ± 35.140 | -39.03 ± 33.130 | -54.64 ± 37.449 | -40.13 ± 32.850 | -44.16 ± 21.761 |
Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score and change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
| score on a scale | Cohort 1 - 10 mg BID | Cohort 1 - Placebo | Cohort 2 - 20 mg QD | Cohort 2- Placebo | Cohort 3 - 5 mg BID | Cohort 3- Placebo |
|---|---|---|---|---|---|---|
| Baseline | 2.67 ± 1.126 | 3.09 ± 0.867 | 2.68 ± 1.179 | 4.04 ± 0.410 | 3.63 ± 0.783 | 2.90 ± 1.110 |
| Day 14 | 1.62 ± 1.234 | 1.70 ± 1.045 | 1.62 ± 1.400 | 1.79 ± 0.979 | 1.84 ± 1.302 | 1.10 ± 0.436 |
| Change from baseline to Day 14 | -1.07 ± 1.485 | -1.39 ± 1.659 | -1.06 ± 1.357 | -2.25 ± 1.247 | -1.79 ± 1.183 | -1.81 ± 1.164 |
Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score percent change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
| Percent change in score | Cohort 1 - 10 mg BID | Cohort 1 - Placebo | Cohort 2 - 20 mg QD | Cohort 2- Placebo | Cohort 3 - 5 mg BID | Cohort 3- Placebo |
|---|---|---|---|---|---|---|
| The Percent Change From Baseline in PAGI-SYM Subscale Score - Heartburn/Regurgitation | -25.45 ± 69.985 | -16.23 ± 121.734 | -34.56 ± 78.627 | -54.50 ± 27.174 | -50.23 ± 29.032 | -59.68 ± 18.912 |
Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score and change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
| score on a scale | Cohort 1 - 10 mg BID | Cohort 1 - Placebo | Cohort 2 - 20 mg QD | Cohort 2- Placebo | Cohort 3 - 5 mg BID | Cohort 3- Placebo |
|---|---|---|---|---|---|---|
| Baseline | 3.60 ± 0.792 | 3.70 ± 0.714 | 3.42 ± 0.859 | 3.63 ± 0.777 | 3.89 ± 0.782 | 3.50 ± 0.250 |
| Day 14 | 2.71 ± 1.109 | 2.27 ± 1.222 | 2.32 ± 1.321 | 1.75 ± 1.173 | 2.36 ± 1.426 | 2.25 ± 1.090 |
| Change from baseline to Day 14 | -0.88 ± 0.915 | -1.43 ± 1.347 | -1.10 ± 1.224 | -1.88 ± 1.665 | -1.53 ± 1.422 | -1.25 ± 1.090 |
Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score percent change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
| Percent change in score | Cohort 1 - 10 mg BID | Cohort 1 - Placebo | Cohort 2 - 20 mg QD | Cohort 2- Placebo | Cohort 3 - 5 mg BID | Cohort 3- Placebo |
|---|---|---|---|---|---|---|
| The Percent Change From Baseline in PAGI-SYM Subscale Score - Fullness/Early Satiety | -24.08 ± 27.288 | -37.09 ± 34.721 | -31.45 ± 36.563 | -47.16 ± 45.857 | -38.04 ± 37.136 | -35.73 ± 30.941 |
Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score and change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
| score on a scale | Cohort 1 - 10 mg BID | Cohort 1 - Placebo | Cohort 2 - 20 mg QD | Cohort 2- Placebo | Cohort 3 - 5 mg BID | Cohort 3- Placebo |
|---|---|---|---|---|---|---|
| Baseline | 2.75 ± 1.022 | 2.97 ± 0.640 | 2.49 ± 0.765 | 3.08 ± 0.957 | 2.74 ± 0.997 | 2.11 ± 1.171 |
| Day 14 | 1.78 ± 1.105 | 1.09 ± 0.967 | 1.29 ± 1.167 | 1.08 ± 1.424 | 1.74 ± 1.498 | 0.89 ± 0.509 |
| Change from baseline to Day 14 | -0.93 ± 1.096 | -1.88 ± 1.195 | -1.20 ± 1.030 | -2.00 ± 1.247 | -1.00 ± 1.155 | -1.22 ± 1.678 |
Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score percent change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
| Percent change in score | Cohort 1 - 10 mg BID | Cohort 1 - Placebo | Cohort 2 - 20 mg QD | Cohort 2- Placebo | Cohort 3 - 5 mg BID | Cohort 3- Placebo |
|---|---|---|---|---|---|---|
| The Percent Change From Baseline in PAGI-SYM Subscale Score - Nausea/Vomiting | -30.39 ± 46.871 | -60.70 ± 37.490 | -50.18 ± 45.677 | -69.55 ± 39.091 | -39.58 ± 33.284 | -35.56 ± 62.923 |
Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score and change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
| score on a scale | Cohort 1 - 10 mg BID | Cohort 1 - Placebo | Cohort 2 - 20 mg QD | Cohort 2- Placebo | Cohort 3 - 5 mg BID | Cohort 3- Placebo |
|---|---|---|---|---|---|---|
| Baseline | 3.84 ± 1.001 | 4.09 ± 0.491 | 3.57 ± 1.387 | 4.00 ± 0.000 | 3.67 ± 0.612 | 3.83 ± 0.289 |
| Day 14 | 2.65 ± 1.314 | 2.45 ± 1.604 | 2.47 ± 1.620 | 2.25 ± 1.500 | 2.67 ± 1.658 | 2.67 ± 1.258 |
| Change from baseline to Day 14 | -1.17 ± 1.227 | -1.64 ± 1.629 | -1.10 ± 1.213 | -1.75 ± 1.500 | -1.00 ± 1.275 | -1.17 ± 1.258 |
Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score percent change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
| Percent change in score | Cohort 1 - 10 mg BID | Cohort 1 - Placebo | Cohort 2 - 20 mg QD | Cohort 2- Placebo | Cohort 3 - 5 mg BID | Cohort 3- Placebo |
|---|---|---|---|---|---|---|
| The Percent Change From Baseline in PAGI-SYM Subscale Score - Bloating | -26.78 ± 39.490 | -39.77 ± 36.291 | -36.38 ± 37.429 | -43.75 ± 37.500 | -30.16 ± 39.260 | -30.36 ± 31.288 |
Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score and change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
| score on a scale | Cohort 1 - 10 mg BID | Cohort 1 - Placebo | Cohort 2 - 20 mg QD | Cohort 2- Placebo | Cohort 3 - 5 mg BID | Cohort 3- Placebo |
|---|---|---|---|---|---|---|
| Baseline | 2.74 ± 1.286 | 3.00 ± 1.245 | 2.27 ± 1.413 | 3.38 ± 0.250 | 3.17 ± 1.479 | 2.67 ± 0.577 |
| Day 14 | 1.82 ± 1.323 | 1.64 ± 1.120 | 1.57 ± 1.450 | 1.25 ± 1.500 | 2.06 ± 1.530 | 1.33 ± 1.155 |
| Change from baseline to Day 14 | -0.97 ± 1.395 | -1.36 ± 1.614 | -0.70 ± 0.978 | -2.13 ± 1.377 | -1.11 ± 1.635 | -1.33 ± 0.577 |
Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score percent change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
| Percent change in score | Cohort 1 - 10 mg BID | Cohort 1 - Placebo | Cohort 2 - 20 mg QD | Cohort 2- Placebo | Cohort 3 - 5 mg BID | Cohort 3- Placebo |
|---|---|---|---|---|---|---|
| The Percent Change From Baseline in PAGI-SYM Subscale Scores - Upper Abdominal Pain | -24.47 ± 80.505 | -50.24 ± 34.116 | -32.81 ± 41.891 | -64.29 ± 42.857 | -37.28 ± 43.374 | -55.56 ± 38.490 |
Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score and change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
| score on a scale | Cohort 1 - 10 mg BID | Cohort 1 - Placebo | Cohort 2 - 20 mg QD | Cohort 2- Placebo | Cohort 3 - 5 mg BID | Cohort 3- Placebo |
|---|---|---|---|---|---|---|
| Baseline | 2.02 ± 1.306 | 2.64 ± 1.164 | 1.93 ± 1.624 | 2.88 ± 0.250 | 3.11 ± 1.537 | 2.17 ± 1.258 |
| Day 14 | 1.25 ± 1.271 | 1.36 ± 1.164 | 1.53 ± 1.356 | 1.50 ± 1.732 | 1.44 ± 1.424 | 1.33 ± 1.155 |
| Change from baseline to Day 14 | -0.79 ± 1.888 | -1.27 ± 1.808 | -0.40 ± 1.021 | -1.38 ± 1.601 | -1.67 ± 1.581 | -0.83 ± 0.764 |
Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score percent change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.
| Percent change in score | Cohort 1 - 10 mg BID | Cohort 1 - Placebo | Cohort 2 - 20 mg QD | Cohort 2- Placebo | Cohort 3 - 5 mg BID | Cohort 3- Placebo |
|---|---|---|---|---|---|---|
| The Percent Change From Baseline in PAGI-SYM Subscale Score - Lower Abdominal Pain | -38.38 ± 71.677 | -25.49 ± 82.970 | -10.91 ± 56.137 | -50.00 ± 57.735 | -52.08 ± 37.456 | -47.62 ± 50.170 |
The Clinical Grading Assessment Scale is a patient and investigator reported outcome instrument for a clinical trial endpoint. Completed at Day 14, the assessment asks subjects about how their stomach/gastroparesis-related problems/symptoms compare to the period before they started treatment in the study based on a 15-point likert scale, where +7 is completely better, 0 is no change, and -7 is very much worse.
| Participants | Cohort 1 - 10 mg BID | Cohort 1 - Placebo | Cohort 2 - 20 mg QD | Cohort 2- Placebo | Cohort 3 - 5 mg BID | Cohort 3- Placebo |
|---|---|---|---|---|---|---|
| Subject Responses — Improved | 17 | 6 | 9 | 3 | 5 | 2 |
| Subject Responses — No change | 5 | 2 | 5 | 1 | 4 | 1 |
| Subject Responses — Worsened | 1 | 1 | 0 | 0 | 0 | 0 |
| Investigator Responses — Improved | 22 | 8 | 11 | 3 | 6 | 2 |
| Investigator Responses — No change | 8 | 3 | 4 | 1 | 3 | 1 |
| Investigator Responses — Worsened | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over Approximately 16 days (14 days of study drug treatment plus 2 days of follow-up). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1- 10 mg BID | 0/30 (0%) | 0/30 (0%) | 7/30 (23.3%) |
| Cohort 2- 20 mg QD | 0/15 (0%) | 0/15 (0%) | 6/15 (40%) |
| Cohort 3- 5 mg BID | 0/9 (0%) | 0/9 (0%) | 1/9 (11.1%) |
| Placebo (Pooled) | 0/18 (0%) | 0/18 (0%) | 2/18 (11.1%) |
| Event | Cohort 1- 10 mg BID | Cohort 2- 20 mg QD | Cohort 3- 5 mg BID | Placebo (Pooled) |
|---|---|---|---|---|
| Electrocardiogram QT ProlongationInvestigations | 1/30 | 2/15 | 0/9 | 0/18 |
| Abdominal Pain LowerGastrointestinal disorders | 0/30 | 0/15 | 1/9 | 0/18 |
| DiarrhoeaGastrointestinal disorders | 3/30 | 1/15 | 0/9 | 0/18 |
| ConstipationGastrointestinal disorders | 0/30 | 1/15 | 0/9 | 0/18 |
| DyspepsiaGastrointestinal disorders | 0/30 | 1/15 | 0/9 | 0/18 |
| HypoglycaemiaMetabolism and nutrition disorders | 1/30 | 1/15 | 0/9 | 0/18 |
| SinusitisInfections and infestations | 0/30 | 1/15 | 0/9 | 0/18 |
| HeadacheNervous system disorders | 0/30 | 1/15 | 0/9 | 0/18 |
| NauseaGastrointestinal disorders | 1/30 | 0/15 | 0/9 | 1/18 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/30 | 0/15 | 0/9 | 1/18 |
| Age, Continuous(years) | Cohort 1- 10 mg BID | Cohort 2- 20 mg QD | Cohort 3- 5 mg BID | Placebo (Pooled) | Total |
|---|---|---|---|---|---|
| Mean | 58.9 ± 7.44 | 58.1 ± 7.00 | 50.7 ± 11.91 | 56.1 ± 11.23 | 57.0 ± 9.25 |
| Sex: Female, Male(Participants) | Cohort 1- 10 mg BID | Cohort 2- 20 mg QD | Cohort 3- 5 mg BID | Placebo (Pooled) | Total |
|---|---|---|---|---|---|
| Female | 26 | 11 | 8 | 13 | 58 |
| Male | 4 | 4 | 1 | 5 | 14 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1- 10 mg BID | Cohort 2- 20 mg QD | Cohort 3- 5 mg BID | Placebo (Pooled) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 19 | 9 | 3 | 14 | 45 |
| Not Hispanic or Latino | 11 | 5 | 6 | 4 | 26 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Cohort 1- 10 mg BID | Cohort 2- 20 mg QD | Cohort 3- 5 mg BID | Placebo (Pooled) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 6 | 3 | 2 | 0 | 11 |
| White | 24 | 12 | 7 | 17 | 60 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 1 |
| Region of Enrollment(participants) | Cohort 1- 10 mg BID | Cohort 2- 20 mg QD | Cohort 3- 5 mg BID | Placebo (Pooled) | Total |
|---|---|---|---|---|---|
| United States | 30 | 15 | 9 | 18 | 72 |
| Gastroparesis type(Participants) | Cohort 1- 10 mg BID | Cohort 2- 20 mg QD | Cohort 3- 5 mg BID | Placebo (Pooled) | Total |
|---|---|---|---|---|---|
| Idiopathic | 7 | 5 | 2 | 7 | 21 |
| Diabetic | 23 | 10 | 7 | 11 | 51 |
| Baseline GEBT T1/2, n(%)(Participants) | Cohort 1- 10 mg BID | Cohort 2- 20 mg QD | Cohort 3- 5 mg BID | Placebo (Pooled) | Total |
|---|---|---|---|---|---|
| <110 kPCD | 11 | 5 | 0 | 7 | 23 |
| >=110 kPCD | 19 | 6 | 2 | 7 | 34 |
| Not included in analysis due to test lot recall | 0 | 4 | 7 | 4 | 15 |
| BMI(kg/m^2) | Cohort 1- 10 mg BID | Cohort 2- 20 mg QD | Cohort 3- 5 mg BID | Placebo (Pooled) | Total |
|---|---|---|---|---|---|
| Mean | 30.16 ± 4.704 | 29.43 ± 6.189 | 28.89 ± 5.859 | 32.00 ± 5.631 | 30.31 ± 5.404 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2019 to primary completion in Dec 2020, 15 months.
Results were first posted in Mar 2026, 5 years 3 months after primary completion. A results delay was requested in Jul 2021.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: CIN-102 · Deudomperidone
CinDome Pharma, Inc.